Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
Executive Summary
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.
You may also be interested in...
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
PhRMA Starts New Year With Familiar Drug Pricing Proposals Targeting The Supply Chain
Hoping to revive interest in rebate reform, PhRMA releases study saying manufacturers retain a shrinking portion of gross branded drug revenues as products move through the supply chain. The pricing distortion underscores the importance of targeting practices by payers and hospitals, the trade group argues.
Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It
Bipartisan effort seems more focused on increasing cost transparency for US health care services, but stakeholders still are expected to raise drug pricing issues.